Skip to content

Research on the Integration of Deng's Internal Medicine and Lv's Micro-Syndrome School in the Diagnosis and Treatment of Diabetes and Coronary Heart Disease

Research on the Integration of Deng's Internal Medicine and Lv's Micro-Syndrome School in the Diagnosis and Treatment of Diabetes and Coronary Heart Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000755
Enrollment
Unknown
Registered
2025-04-15
Start date
2025-04-30
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes coronary heart disease unspecified

Interventions

Lü's School of Minor Syndromes:Formula for Nourishing Qi and Yin, Unblocking Meridians, and Dissolving Nodules with Modifications
Fusion Group:Harmony Method
Deng's Internal Medicine Group:Wen Dan Decoction with Modifications

Sponsors

Beijing University of Chinese Medicine Dongzhimen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed and treated by academic successors of the [specific] school of traditional Chinese medicine who meet the above-mentioned diagnostic criteria of both traditional Chinese medicine and Western medicine. (2) No gender restrictions aged between 18 and 80 years old. (3) Patients who have not participated in any other clinical trials within the past 3 months. (4) The participants themselves have been informed and have given their consent and they voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with diabetes and coronary heart disease complicated by severe complications such as myocardial infarction heart failure atrial fibrillation post-coronary artery bypass grafting diabetic nephropathy diabetic foot diabetic retinopathy etc. are excluded. (2) Pregnant or breastfeeding women as well as women who plan to become pregnant or do not have a contraception plan. (3) Patients with abnormal liver or kidney function. (4) Patients with coagulation disorders or abnormal immune system severe organ dysfunction severe mental illness or cognitive impairment are excluded. (5) Individuals known to be allergic to the drugs used in this study.

Design outcomes

Primary

MeasureTime frame
Cardiac function indicators;Glucose metabolism indicators;

Secondary

MeasureTime frame
Blood lipid levels;Safety Indicators;TCM Syndrome Indices;

Countries

China

Contacts

Public Contactwuhuanlin

Beijing University of Chinese Medicine Dongzhimen Hospital

wuhuanlinboshi@aliyun.com13822212111

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026